Logo Image
Commentary|Podcasts|November 13, 2025

Improving Site Satisfaction Through Better Technology and Collaboration

Melissa Hutchens, vice president of research & benchmarking at WCG, and Jimmy Garza, senior director of clinical operations at Bayer, discuss findings from the latest WCG CenterWatch Global Site Relationship Survey, revealing a decline in overall site satisfaction. They explore key drivers behind this trend, including technology usability, communication gaps, and limited site input in protocol design, and share actionable approaches to strengthen sponsor-site partnerships and improve study execution.

Melissa Hutchens, vice president of research & benchmarking at WCG, and Jimmy Garza, senior director of clinical operations at Bayer, discuss:

  • Key findings from the 2025 WCG CenterWatch Global Site Relationship Survey and what’s driving the decline in site satisfaction
  • How sponsors can leverage technology to enhance, not hinder, site efficiency and usability
  • Strategies to incorporate site feedback earlier in protocol design and planning
  • Practical ways to strengthen communication, support study coordinators, and improve overall sponsor-site collaboration
  • And more!

Related to this article

View more
Recruitment in the Age of AI: Q&A with John Worden, Javara
Recruitment in the Age of AI: Q&A with John Worden, Javara
In this Q&A, John Worden, chief commercial officer at Javara, discusses why clinical trial recruitment has remained stubbornly one-size-fits-all, how AI can identify patients at scale without displacing the clinician relationships that drive trust, and what care-integrated research engagement needs to look like for health systems, sponsors, and sites.
Read more
Introducing The Human Side of Clinical Trials
Introducing The Human Side of Clinical Trials
This pilot episode of The Human Side of Clinical Trials introduces a framework from Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., exploring why operational failures in clinical trials often trace back to gaps in human readiness rather than process design alone.
Read more